We also found statistically significant differences in the expression of PDL-1 in tumor cells (TC) and immune cells (IC) between groups with different CXCR3 pathway activation levels (Kruskal–Wallis test, p < 0.001, Additional file 4: Figure S4A, B). Here, CXCR3 is linked to neoplasm.